Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit

Many human cancers involve up-regulation of the phosphoinositide 3-kinase PI3Kα, with oncogenic mutations identified in both the p110α catalytic and the p85α regulatory subunits. We used crystallographic and biochemical approaches to gain insight into activating mutations in two noncatalytic p110α domains—the adaptor-binding and the helical domains. A structure of the adaptor-binding domain of p110α in a complex with the p85α inter–Src homology 2 (inter-SH2) domain shows that oncogenic mutations in the adaptor-binding domain are not at the inter-SH2 interface but in a polar surface patch that is a plausible docking site for other domains in the holo p110/p85 complex. We also examined helical domain mutations and found that the Glu545 to Lys545 (E545K) oncogenic mutant disrupts an inhibitory charge-charge interaction with the p85 N-terminal SH2 domain. These studies extend our understanding of the architecture of PI3Ks and provide insight into how two classes of mutations that cause a gain in function can lead to cancer.

[1]  Itay Mayrose,et al.  ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures , 2005, Nucleic Acids Res..

[2]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[3]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[4]  M. Huber,et al.  Mutations in the inter-SH2 domain of the regulatory subunit of phosphoinositide 3-kinase: effects on catalytic subunit binding and holoenzyme function , 2006, Biological chemistry.

[5]  K. Okkenhaug,et al.  New Responsibilities for the PI3K Regulatory Subunit p85α , 2001, Science's STKE.

[6]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[7]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[8]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[9]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[10]  Eliah Aronoff-Spencer,et al.  The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Wymann,et al.  Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. , 2005, Current opinion in cell biology.

[12]  A. Carrera,et al.  The p85 Regulatory Subunit Controls Sequential Activation of Phosphoinositide 3-Kinase by Tyr Kinases and Ras* , 2002, The Journal of Biological Chemistry.

[13]  L. Cantley,et al.  Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. , 1993, The Journal of biological chemistry.

[14]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[15]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[16]  M. Girvin,et al.  Mechanism of Constitutive Phosphoinositide 3-Kinase Activation by Oncogenic Mutants of the p85 Regulatory Subunit* , 2005, Journal of Biological Chemistry.

[17]  M. Zvelebil,et al.  Activation Loop Sequences Confer Substrate Specificity to Phosphoinositide 3-Kinase α (PI3Kα) , 2001, The Journal of Biological Chemistry.

[18]  S. Harrison,et al.  Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes , 1996, Nature Structural Biology.

[19]  J. Backer,et al.  Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. , 1998, The Journal of biological chemistry.

[20]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[21]  T. Kawabe,et al.  Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.

[22]  C. Rommel,et al.  Phosphoinositide 3-kinases as targets for therapeutic intervention. , 2004, Current pharmaceutical design.

[23]  Marketa Zvelebil,et al.  Phosphoinositide 3-kinase signalling--which way to target? , 2003, Trends in pharmacological sciences.

[24]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[25]  M. Kasuga,et al.  PI 3‐kinase: structural and functional analysis of intersubunit interactions. , 1994, The EMBO journal.

[26]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[27]  P. Workman,et al.  Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. , 2004, Biochemical Society transactions.

[28]  J. Backer,et al.  Regulation of the p85/p110 Phosphatidylinositol 3′-Kinase: Stabilization and Inhibition of the p110α Catalytic Subunit by the p85 Regulatory Subunit , 1998, Molecular and Cellular Biology.

[29]  References , 1971 .

[30]  良二 上田.  J. Appl. Cryst.の発刊に際して , 1970 .

[31]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Roger L. Williams,et al.  Phosphoinositide 3-kinases as drug targets in cancer. , 2005, Current opinion in pharmacology.

[33]  B. Vanhaesebroeck,et al.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers , 2007, Proceedings of the National Academy of Sciences.

[34]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[35]  P. Tsichlis,et al.  PDK2: A Complex Tail in One Akt , 2001, Science's STKE.